Human Immunodeficiency Virus Type 1 (HIV-1) Drug Resistance (PhenoSense GT Plus Integrase)
HIV-1 combined pheno- and genotyping test provides antiretroviral susceptibility information for protease inhibitors (PI), reverse transcriptase inhibitors (NRTI, NNRTI), and integrase inhibitors (INI). Preferred test for patients with known or suspected complex drug resistance patterns (eg, suboptimal virologic response to treatment and viral load rebound).
Lavender (EDTA) or plasma preparation tube (PPT).
Separate plasma from cells within 6 hours of collection. Transfer 5 mL plasma to an ARUP Standard Transport Tube and freeze immediately. (Min: 3 mL)
CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered.
Provide patient's most recent viral load and viral load collection date.
Ambient: Unacceptable; Refrigerated: Unacceptable; Frozen: 2 weeks
No compliance statements are in use for this test.
Procedure should be used for patients with documented HIV-1 infection and viral loads greater than 500 copies/mL.
87900; 87901; 87903; 87904 x14; 87906
|Component Test Code*||Component Chart Name||LOINC|
|0092074||Viral Load Date||19151-0|
|2010809||EER HIV-1 PhenoSense GT Plus Integrase|